Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Virotherapy Shows Promise Against Multiple Myeloma

Published: Friday, May 16, 2014
Last Updated: Friday, May 16, 2014
Bookmark and Share
A Mayo Clinic proof of principle clinical trial, demonstrated that virotherapy, destroying cancer with a virus that infects and kills cancer cells but spares normal tissues, can be effective against multiple myeloma.

Two patients in the study received a single intravenous dose of an engineered measles virus (MV-NIS) that is selectively toxic to myeloma plasma cells. Both patients responded, showing reduction of both bone marrow cancer and myeloma protein. One patient, a 49-year-old woman, experienced complete remission of myeloma and has been clear of the disease for over six months.

“This is the first study to establish the feasibility of systemic oncolytic virotherapy for disseminated cancer,” says Stephen Russell, M.D., Ph.D., Mayo Clinic hematologist, first author of the paper and co-developer of the therapy. “These patients were not responsive to other therapies and had experienced several recurrences of their disease.”

Multiple myeloma is a cancer of plasma cells in the bone marrow, which also causes skeletal or soft tissue tumors. This cancer usually responds to immune system-stimulating drugs, but eventually overcomes them and is rarely cured.

In their article, the researchers explain they were reporting on these two patients because they were the first two studied at the highest possible dose, had limited previous exposure to measles, and therefore fewer antibodies to the virus, and essentially had no remaining treatment options.

Oncolytic virotherapy – using re-engineered viruses to fight cancer – has a history dating back to the 1950s. Thousands of cancer patients have been treated with oncolytic viruses from many different virus families (herpesviruses, poxviruses, common cold viruses, etc.). However, this study provides the first well-documented case of a patient with disseminated cancer having a complete remission at all disease sites after virus administration. 

The second patient in the paper, whose cancer did not respond as well to the virus treatment, was equally remarkable because her imaging studies provided a clear proof that the intravenously administered virus specifically targeted the sites of tumor growth. This was done using high-tech imaging studies, which were possible only because the virus had been engineered with a 'snitch gene' — an easily identifiable marker — so researchers could accurately determine its location in the body.

More of the MV-NIS therapy is being manufactured for a larger, phase 2 clinical trial. The researchers also want to test the effectiveness of the virotherapy in combination with radioactive therapy (iodine-131) in a future study.

The findings appear in the journal Mayo Clinic Proceedings

Other authors include Mark Federspiel, Ph.D., Kah-Whye Peng, Ph.D., M.Med., Caili Tong, David Dingli, M.D., Ph.D., William Morice, M.D., Ph.D., Val Lowe, M.D., Michael O’Connor, Ph.D., Robert Kyle, M.D., Nelson Leung, M.D., Francis Buadi, M.D., S. Vincent Rajkumar, M.D., Morie Gertz, M.D., Martha Lacy, M.D., and senior and corresponding author Angela Dispenzieri, M.D., all of Mayo Clinic.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Wednesday, August 26, 2015
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Tuesday, August 18, 2015
Mayo, Baylor Collaborate
They aim to study genomic links to drug metabolism and other interactions which could be used to provide more tailored patient care.
Friday, May 15, 2015
First Steps in Formation of Pancreatic Cancer Identified
Researchers at Mayo Clinic’s campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.
Tuesday, November 11, 2014
Mayo Clinic, UMMC Expand Relationship
Mayo Clinic and the University of Mississippi Medical Center have signed an agreement to broaden and deepen their collaboration in clinical trials, other medical research and education.
Monday, October 06, 2014
Mayo Clinic, Whole Biome Announce Collaboration
Joint development of microbiome diagnostic testing to focus on women’s health and preterm labor.
Tuesday, May 20, 2014
Mayo Clinic Researchers Identify Role of Cul4 Molecule in Genome Instability and Cancer
Cul4 helps to deposit DNA-packaging histone proteins onto DNA, an integral step to help compact the genetic code.
Monday, November 11, 2013
Mayo Clinic Launches Biobank in Arizona, Expanding Diversity Research
Mayo Clinic biobank will support studies in obesity, metabolism and diabetes, all areas of special concern in the Latino population.
Tuesday, October 15, 2013
Mayo Florida Receives $5M for Individualized Medicine Clinic
The donation from Florida residents Cecilia and Dan Carmichael will accelerate translation of research to patient care.
Wednesday, August 21, 2013
Mayo Clinic Forms Joint Venture with Cancer Genetics
OncoSpire Genomics will seek to discover and commercialize biomarkers for multiple cancer types.
Thursday, May 23, 2013
Why Does Smallpox Vaccine Shield Some, Not Others? It's in the Genes
How well people are protected by the smallpox vaccine depends on more than the quality of the vaccination: individual genes can alter their response, Mayo Clinic research shows.
Tuesday, April 23, 2013
Saliva Gland Test for Parkinson's Shows Promise
Findings described as a "big step forward" for research and treatment of Parkinson's disease.
Wednesday, January 16, 2013
Mayo Clinic Receives Funding for Gut Function Biomarker Research
The program aims to identify and validate biomarkers that can assess gut function and guide new ways to improve the health and development of children in the developing world.
Friday, December 28, 2012
Men with Fibromyalgia Often Go Undiagnosed, Mayo Clinic Study Suggests
There is not yet a diagnostic test to establish that someone has fibromyalgia, there is no cure and many symptoms can overlap with or get mistaken for other conditions.
Friday, December 21, 2012
Mitochondrial Dysfunction Present Early in Alzheimer’s, Before Memory Loss
Using genetic mouse models, Mayo Clinic researchers have discovered that mitochondria in the brain are dysfunctional early in the disease.
Thursday, March 01, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!